SB-204990, a γ-lactone prodrug of SB-201076, is a potent and specific inhibitor of ATP citrate lyase (ACLY). SB 204990 effectively limits SARS-CoV-2 replication in vivo.

Brand: BCM

 

Target: ATP Citrate Lyase

 

Signaling Pathways: Metabolism

 

In Vivo: SB 204990 is absorbed into the systemic circulation when administered orally to rats. SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats when administered in the diet (0.05-0.25%, w/w) for 1 week. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels.

 

Melting Point: 87-89 °C

 

Boiling Point: 571.6±40.0 °C(Predicted)

 

pKa: 4.33±0.10(Predicted)

 

Solubility: Soluble in DMSO; Soluble in Water; Soluble in Ethanol.

 

Isomeric SMILES: C1[C@H](OC(=O)[C@]1(CC(=O)O)O)CCCCCCC2=C(C=C(C=C2)Cl)Cl  

 

InChIKey: YTRNLFYTHYWDAU-KDOFPFPSSA-N  

 

InChI: InChI=1S/C18H22Cl2O5/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14-10-18(24,11-16(21)22)17(23)25-14/h7-9,14,24H,1-6,10-11H2,(H,21,22)/t14-,18+/m1/s1

 

Attribute
[Chem Name]	2-[(3S,5R)-5-[6-(2,4-dichlorophenyl)hexyl]-3-hydroxy-2-oxooxolan-3-yl]acetic acid
[Synonym]	SB 204990
[CAS No.]	154566-12-8
[MDL No.]	MFCD28127018
[Formula]	C18H22Cl2O5
[Molecular]	389.27
[Form]	A crystalline solid
[Storage]	Sealed in dry, 2-8°C

Goods Tag